Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Checked against the public recordLast updated Mar 3, 2022 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- SCRI Development Innovations, LLC
- Interventions being studied
- Drug: Docetaxel; Drug: Gemcitabine; Drug: Carboplatin; Radiation: Radiation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Histologically confirmed non-small cell lung cancer * Must be operable candidate * Clinical stage IB, II, and select III non-small cell lung cancer are eligible * Measurable or evaluable disease * Able to perform activities of daily living with minimal assistance * Must be \> 18 years of age * Adequate bone marrow, liver or kidney * No previous chemotherapy or radiation therapy for non-small cell lung cancer * Moderate to severe peripheral neuropathy * Understand the nature of this study and give written informed consent. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: * Stage IV disease * History of prior malignancy within five years * Women who are pregnant or breast-feeding Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Tennessee Oncology, PLLCNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 3, 2022. Always confirm current availability with the study team.